Dr Marco Loddo is Co-Founder and Scientific Director at Oncologica
Dr Loddo is responsible for directing all operational, technical and scientific aspects of the clinical services, contract research and R&D activities. He’s also responsible for directing the business strategy and administrative matters of the company. He also directs the development of strategies to ensure effective achievement of scientific/business objectives, including planning, implementation, monitoring and evaluating the delivery of clinical services, completion of contract research tasks and projects, development of commercial and financial strategies for capital expenditures, staff resources, marketing, and contracts.
Dr Marco Loddo BSc, PhD undertook his post-graduate training in Professor Williams’ laboratory within the Department of Pathology at University College London in which he combined anatomical pathology, cell cycle research and functional genomics to identify new diagnostic and therapeutic intervention strategies for the improved clinical management of cancer patients.
Dr Loddo’s background and experience includes biomarker discovery and validation, development of companion diagnostics for molecularly targeted therapies, translational medicine and clinical trials. Dr Loddo has now brought this wealth of experience in molecular pathology analytics and targeted therapies to Oncologica® in his role as the Scientific Director for the company.
Published Research Papers
Published: March 25, 2022 DOI: https://doi.org/10.1371/journal.pone.0245817
Gareth H Williams, Alexander Llewelyn, Robert Thatcher, Keeda-Marie Hardisty, Marco Loddo
SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom
EClinical Medicine by the Lancet Published:July 14, 2021 DOI: https://doi.org/10.1016/j.eclinm.2021.101021
Gareth H Williams, Alexander Llewelyn, Ruben Brandao, Kaiya Chowdhary,Keeda-Marie Hardisty, Marco Loddo (2021)
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial
Front Oncol. 2021; 11: 686776. Published online 2021 Jun 28. doi: https://doi.org/10.3389/fonc.2021.686776
Alfredo Molteni, Alice Bruson, Carla Strina, Carlo Azzini, Daniele Generali, Davide Cerra, Elena Marasco, Elisa Zago, Fabiola Giudici, Francesco Schettini, Gareth H Williams, Giovanni Scambia, Giuseppina Barbieri, Giuseppina Ferrero, Ida Paris, Luciano Xumerle, Manuela Milani, Marco Loddo, Marco Ungari, Maria Chiara Lazzari, Maria Rosa Cappelletti, Marianna Sirico, Nicoletta Ziglioli, Ottavia Bernocchi, Sergio Aguggini, Silvia Paola Corona, Valeria Cervoni
J Clin Oncol 38: 2020 (suppl; abstr e13642) DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.e13642
Loddo M, Hardisty KM, Thatcher RP, Haddow TE, Williams GH (2020)
J Clin Oncol 38: 2020 (suppl; abstr e13521) DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.e13521
Williams GH, Thatcher RP, Haddow TE, Hardisty KM, Loddo M (2020)
J Clin Oncol 38: 2020 (suppl; abstr e13517) DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.e13517
Williams GH, Thatcher RP, Nevado B, Haddow TE, Hardisty KM, Loddo M (2020)